Capoten 25mg Tablets is primarily indicated in conditions like Congestive heart failure, Congestive heart failure (adjunct), Diabetic nephropathy, Diabetic retinopathy, Essential hypertension, Essential hypertension (mild to moderate), severe hypertension resistant to other treatment, Gastric acid reduction during anaesthesia, Hypertension, Iron deficiency anaemia, Prophylaxis of acid aspiration, Renal hypertension, Scleroderma renal crisis.
Capoten 25mg Tablets is contraindicated in conditions like Renal diseases, Collagen vascular disease, Renal artery stenosis.
The severe or irreversible adverse effects of Capoten 25mg Tablets, which give rise to further complications include Renal damage, Proteinuria.Capoten 25mg Tablets produces potentially life-threatening effects which include Hyperkalemia, Neutropenia, which are responsible for the discontinuation of Capoten 25mg Tablets therapy. The signs and symptoms that are produced after the acute overdosage of Capoten 25mg Tablets include Hypotension, Respiratory distress, Angioedema, Laryngeal obstruction. The symptomatic adverse reactions produced by Capoten 25mg Tablets are more or less tolerable and if they become severe,
White blood cells (W.B.Cs) counts and urinary protein estimation should be done before and during treatment Capoten 25mg Tablets therapy can cause neutropenia or agranulocytosis. Patients with renal disease, patients with immunosuppression or receiving immunosuppressives, and patients with collagen vascular disease or autoimmune disease are at a greater risk for developing these complications. It should be used with caution in patients with pre-existing bone marrow depression. The dose should be adjusted in patients with renal impairment. It should be used cautiously in patients with congestive heart failure. Initial doses should be lower than in the treatment of hypertension becauseof a greater risk of developing hypotension. It should not be administered to patients with pre-existing renal artery stenosis. Renal function should be monitored closely during the first 2 weeks after initiating therapy. It should be discontinued if renal function worsens acutely. Other types of renal disease can actually improve during Capoten 25mg Tablets therapy. The dose should be adjusted inpatients with renal impairment. It should be used with caution patients with hyperkalemia. It is classified as pregnancy category C and should be used with caution during pregnancy only if clearly needed.